AtheroNova names Shaw as new clinical affairs officer
AtheroNova, a biotech company focused on compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, has appointed Joan E. Shaw, MT (ASCP), SCC as senior director of clinical operations.
Shaw brings more than 20 years of drug development experience leading to successful NDA submissions and product launches for leading organizations such as AstraZeneca and DuPont Pharmaceuticals. Between 2002 and 2012, she served in multiple areas of AstraZeneca ultimately serving as executive director of clinical operations in the Wilmington, Del., headquarters. Prior to AstraZeneca, Shaw led the discovery and development project management department at DuPont Pharmaceuticals, where she was responsible for planning the strategic clinical development of several new drugs including ReVia for alcoholism, Cozaar, and Sustiva to fight HIV infection.